logo
  

AVITA Gets FDA IDE Approval Of Soft Tissue Reconstruction Pivotal Clinical Trial

AVITA Medical (AVMXY.OB) on Monday announced that the FDA has approved the company's Investigational Device Exemption (IDE) application to conduct a study of the Autologous Cell Harvesting Device RECELL in combination with meshed autografting for the treatment of acute soft tissue injuries, defects, and reconstruction.

The study is expected to start in 6 months.

The RECELL System was approved by the U.S. FDA in September 2018, for use in the treatment of acute thermal burns in patients 18 years and older.

The total product sales of RECELL System in the year ended June 30, 2019, were
A$7.7 million compared to A$1.19 million in the prior year.

AVMXY.OB closed Monday's trading at $7.12, unchanged from the previous day's close.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Omaha, Nebraska- based Greater Omaha Packing is recalling around 295,236 pounds of raw beef products citing the possible presence of E. coli O157:H7, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS said. The raw beef products intended for non-intact use were produced on July 13. Consumer goods giant Procter & Gamble Co. (PG) on Friday reported a four percent increase in profit for the fourth quarter from last year, driven by net sales growth across its operating segments, partially offset by a reduction in operating margin. Both revenue and core earnings per share for the quarter beat analysts' estimates. Looking ahead, the company also initiated outlook for fiscal 2022. While reporting financial results for the second quarter on Friday, Colgate-Palmolive Co. (CL) maintained its earnings, adjusted earnings and sales growth guidance for the full-year 2021. For fiscal 2021, the company now expects earnings per share to grow at the lower end of its low to mid-single-digit...
Follow RTT